565 related articles for article (PubMed ID: 22286128)
1. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
3. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
4. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
Grembecka J; Belcher AM; Hartley T; Cierpicki T
J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
[TBL] [Abstract][Full Text] [Related]
8. A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia.
Ozyerli-Goknar E; Nizamuddin S; Timmers HTM
ChemMedChem; 2021 May; 16(9):1391-1402. PubMed ID: 33534953
[TBL] [Abstract][Full Text] [Related]
9. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
10. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
11. Challenges and opportunities in targeting the menin-MLL interaction.
Cierpicki T; Grembecka J
Future Med Chem; 2014 Mar; 6(4):447-62. PubMed ID: 24635524
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide.
Yue L; Du J; Ye F; Chen Z; Li L; Lian F; Zhang B; Zhang Y; Jiang H; Chen K; Li Y; Zhou B; Zhang N; Yang Y; Luo C
Org Biomol Chem; 2016 Sep; 14(36):8503-19. PubMed ID: 27541268
[TBL] [Abstract][Full Text] [Related]
13. Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong
Xu S; Aguilar A; Huang L; Xu T; Zheng K; McEachern D; Przybranowski S; Foster C; Zawacki K; Liu Z; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2020 May; 63(9):4997-5010. PubMed ID: 32338903
[TBL] [Abstract][Full Text] [Related]
14. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
[TBL] [Abstract][Full Text] [Related]
15. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
16. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.
Xu S; Aguilar A; Xu T; Zheng K; Huang L; Stuckey J; Chinnaswamy K; Bernard D; Fernández-Salas E; Liu L; Wang M; McEachern D; Przybranowski S; Foster C; Wang S
Angew Chem Int Ed Engl; 2018 Feb; 57(6):1601-1605. PubMed ID: 29284071
[TBL] [Abstract][Full Text] [Related]
17. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
18. The role of menin in hematopoiesis.
Maillard I; Hess JL
Adv Exp Med Biol; 2009; 668():51-7. PubMed ID: 20175452
[TBL] [Abstract][Full Text] [Related]
19. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
[TBL] [Abstract][Full Text] [Related]
20. Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
Yokoyama A; Cleary ML
Cancer Cell; 2008 Jul; 14(1):36-46. PubMed ID: 18598942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
